Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Viksmoen Watle

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Human Vaccines & Immunotherapeutics|August 23, 2016
Ebola vaccines - Where are we?Sara Viksmoen Watle, Gunnstein Norheim, John-Arne Røttingen
Vaccine|June 19, 2023
Adherence to vaccination guidelines of patients with complete splenectomy in Norway, 2008-2020Saima Orangzeb, Sara Viksmoen Watle, Dominique A Caugant
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 8, 2023
Invasive meningococcal disease in Norway in the two decades before the COVID-19 pandemicOla Brønstad Brynildsrud, Sara Viksmoen Watle, Kristian Alfsnes, et al.
Human Vaccines & Immunotherapeutics|February 25, 2021
Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccineSara Viksmoen Watle, Lisbeth Meyer Næss, Gro Tunheim, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|October 14, 2009
[Increased detection of malformations of kidneys and the urinary tract]Hans Randby, Alf Meberg, Hussain A G Yassin, et al.
BMC Public Health|May 1, 2026
"Why should I pay for this vaccine?" - Norwegian adolescents views on meningococcal vaccinationRebecca Nybru Gleditsch, Sara Viksmoen Watle, Bo T Hansen, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 3, 2021
Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021Elina Seppälä, Lamprini Veneti, Jostein Starrfelt, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 27, 2022
Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patientsRobert Whittaker, Anja Bråthen Kristofferson, Beatriz Valcarcel Salamanca, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|May 17, 2024
Increase in invasive group A streptococcal infections (iGAS) in children and older adults, Norway, 2022 to 2024Beatriz Valcarcel Salamanca, Pascale Renée Cyr, Yngvild Emblem Bentdal, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 9, 2023
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022Lamprini Veneti, Jacob Dag Berild, Sara Viksmoen Watle, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Human Vaccines & Immunotherapeutics|August 23, 2016
Ebola vaccines - Where are we?Sara Viksmoen Watle, Gunnstein Norheim, John-Arne Røttingen
Vaccine|June 19, 2023
Adherence to vaccination guidelines of patients with complete splenectomy in Norway, 2008-2020Saima Orangzeb, Sara Viksmoen Watle, Dominique A Caugant
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 8, 2023
Invasive meningococcal disease in Norway in the two decades before the COVID-19 pandemicOla Brønstad Brynildsrud, Sara Viksmoen Watle, Kristian Alfsnes, et al.
Human Vaccines & Immunotherapeutics|February 25, 2021
Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccineSara Viksmoen Watle, Lisbeth Meyer Næss, Gro Tunheim, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|October 14, 2009
[Increased detection of malformations of kidneys and the urinary tract]Hans Randby, Alf Meberg, Hussain A G Yassin, et al.
BMC Public Health|May 1, 2026
"Why should I pay for this vaccine?" - Norwegian adolescents views on meningococcal vaccinationRebecca Nybru Gleditsch, Sara Viksmoen Watle, Bo T Hansen, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 3, 2021
Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021Elina Seppälä, Lamprini Veneti, Jostein Starrfelt, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 27, 2022
Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patientsRobert Whittaker, Anja Bråthen Kristofferson, Beatriz Valcarcel Salamanca, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|May 17, 2024
Increase in invasive group A streptococcal infections (iGAS) in children and older adults, Norway, 2022 to 2024Beatriz Valcarcel Salamanca, Pascale Renée Cyr, Yngvild Emblem Bentdal, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 9, 2023
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022Lamprini Veneti, Jacob Dag Berild, Sara Viksmoen Watle, et al.
Pageof 2